ArtivaBio is a groundbreaking oncology company dedicated to making safe and effective cell therapies accessible to cancer patients. With a strong focus on Manufacturing-First, they have developed the AlloNK TM platform that enables the advancement of highly scaled, off-the-shelf, allogeneic natural killer (NK) cell therapies. This innovative platform allows for outpatient administration and shows great promise in treating hematologic cancers and solid tumors.

ArtivaBio's pipeline includes both non-genetically modified NK cell and CAR-NK cell therapies. Their non-genetically modified NK cells are used as ADCC enhancers in patients undergoing monoclonal antibody therapy, while their CAR-NK cell therapies leverage the innate biology and safety features of NK cells, enhancing their efficacy with chimeric antigen receptors. By addressing previous challenges in cell therapy, ArtivaBio delivers potentially life-saving treatments that are safe, effective, scalable, versatile, and cost-effective.

Their mission is to expand patient access to these therapies and improve the treatment of cancer. To stay updated on their groundbreaking research and advancements, sign up for their news updates